Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals (Nasdaq: PHAT) will participate in two key investor conferences in June 2024. The company will present at the Jefferies Global Healthcare Conference in New York on June 5 at 12:30 p.m. ET, and at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach on June 11 at 2:40 p.m. ET. Both events will feature live webcasts and archived recordings available on Phathom's website for 90 days post-conference. Management will also hold one-on-one meetings throughout both conferences.
- Participation in high-profile investor conferences can increase visibility and investor interest in PHAT.
- Live webcasts and archived recordings provide broader access to company presentations and updates.
- One-on-one meetings with investors offer personalized engagement opportunities, potentially attracting investments.
- No new product announcements or financial updates were disclosed in the PR.
- High costs associated with participation in multiple conferences may impact operating expenses.
FLORHAM PARK, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in June:
Jefferies Global Healthcare Conference in New York, NY
Date: Wednesday, June 5, 2024
Live Webcast: 12:30 p.m. ET
Management to participate in one-on-one meetings throughout the conference
Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, FL
Date: Tuesday, June 11, 2024
Live Webcast: 2:40 p.m. ET
Management to participate in one-on-one meetings throughout the conference
To access the live webcast and archived recordings of each event, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. Recordings will be available for 90 days following the conclusion of each meeting.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the treatment of Erosive GERD and relief of related heartburn in adults, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the Company’s website at www.phathompharma.com and follow the Company on LinkedIn and X.
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
© 2024 Phathom Pharmaceuticals. All rights reserved.
![](https://ml.globenewswire.com/media/M2I2NmEzMmUtOTZmNi00OGUzLThmNjItZjliYTg2NGYzMDljLTEyMDExMjU=/tiny/Phathom-Pharmaceuticals.png)
FAQ
When will Phathom Pharmaceuticals present at the Jefferies Global Healthcare Conference?
What time is Phathom Pharmaceuticals' webcast at the Goldman Sachs 45th Annual Global Healthcare Conference?
How can I access Phathom Pharmaceuticals' conference presentations?